Back to mobile site

Needham Says ArQule's (ARQL) Derazantinib Partnership a Double Positive

April 17, 2018 12:47 PM EDT Send to a Friend
Needham & Company maintains Buy on ArQule (NASDAQ: ARQL) price target of $5.00.Analyst Chad Messer comments "This morning ArQule announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login